These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 23232940)
1. Cancer-associated fibroblasts do not respond to combined irradiation and kinase inhibitor treatment. Affolter A; Schmidtmann I; Mann WJ; Brieger J Oncol Rep; 2013 Feb; 29(2):785-90. PubMed ID: 23232940 [TBL] [Abstract][Full Text] [Related]
2. Activation of mitogen-activated protein kinase extracellular signal-related kinase in head and neck squamous cell carcinomas after irradiation as part of a rescue mechanism. Affolter A; Fruth K; Brochhausen C; Schmidtmann I; Mann WJ; Brieger J Head Neck; 2011 Oct; 33(10):1448-57. PubMed ID: 21928417 [TBL] [Abstract][Full Text] [Related]
3. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520 [TBL] [Abstract][Full Text] [Related]
4. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cohen EE; Lingen MW; Zhu B; Zhu H; Straza MW; Pierce C; Martin LE; Rosner MR Cancer Res; 2006 Jun; 66(12):6296-303. PubMed ID: 16778206 [TBL] [Abstract][Full Text] [Related]
5. Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling. Hehlgans S; Eke I; Cordes N Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e669-76. PubMed ID: 22483702 [TBL] [Abstract][Full Text] [Related]
6. Reactive oxygen species activation of MAPK pathway results in VEGF upregulation as an undesired irradiation response. Drigotas M; Affolter A; Mann WJ; Brieger J J Oral Pathol Med; 2013 Sep; 42(8):612-9. PubMed ID: 23480207 [TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Krysan K; Reckamp KL; Dalwadi H; Sharma S; Rozengurt E; Dohadwala M; Dubinett SM Cancer Res; 2005 Jul; 65(14):6275-81. PubMed ID: 16024629 [TBL] [Abstract][Full Text] [Related]
8. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells. Ko JC; Ciou SC; Jhan JY; Cheng CM; Su YJ; Chuang SM; Lin ST; Chang CC; Lin YW Mol Cancer Res; 2009 Aug; 7(8):1378-89. PubMed ID: 19671683 [TBL] [Abstract][Full Text] [Related]
9. The enhancement of tumor radioresponse by combined treatment with cepharanthine is accompanied by the inhibition of DNA damage repair and the induction of apoptosis in oral squamous cell carcinoma. Harada T; Harada K; Ueyama Y Int J Oncol; 2012 Aug; 41(2):565-72. PubMed ID: 22664937 [TBL] [Abstract][Full Text] [Related]
10. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Gysin S; Lee SH; Dean NM; McMahon M Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308 [TBL] [Abstract][Full Text] [Related]
11. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Vicent S; Garayoa M; López-Picazo JM; Lozano MD; Toledo G; Thunnissen FB; Manzano RG; Montuenga LM Clin Cancer Res; 2004 Jun; 10(11):3639-49. PubMed ID: 15173070 [TBL] [Abstract][Full Text] [Related]
12. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction. Manov I; Pollak Y; Broneshter R; Iancu TC FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999 [TBL] [Abstract][Full Text] [Related]
14. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126. Gao J; Niwa K; Takemura M; Sun W; Onogi K; Wu Y; Seishima M; Mori H; Tamaya T Int J Oncol; 2005 Mar; 26(3):737-44. PubMed ID: 15703831 [TBL] [Abstract][Full Text] [Related]
15. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC. Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633 [TBL] [Abstract][Full Text] [Related]
16. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population. Ciccarelli C; Vulcano F; Milazzo L; Gravina GL; Marampon F; Macioce G; Giampaolo A; Tombolini V; Di Paolo V; Hassan HJ; Zani BM Mol Cancer; 2016 Feb; 15():16. PubMed ID: 26897742 [TBL] [Abstract][Full Text] [Related]
17. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2. Chang CM; Chang PY; Tu MG; Lu CC; Kuo SC; Amagaya S; Lee CY; Jao HY; Chen MY; Yang JS Oncol Rep; 2012 Nov; 28(5):1799-807. PubMed ID: 22923287 [TBL] [Abstract][Full Text] [Related]
18. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126. Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells. Yin ZJ; Jin FG; Liu TG; Fu EQ; Xie YH; Sun RL J Surg Res; 2011 Dec; 171(2):675-83. PubMed ID: 20605584 [TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Beloueche-Babari M; Jackson LE; Al-Saffar NM; Workman P; Leach MO; Ronen SM Cancer Res; 2005 Apr; 65(8):3356-63. PubMed ID: 15833869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]